SARS-CoV-2 N protein monoclonal antibody, its preparation method and application
By preparing the SARS-CoV-2 N protein monoclonal antibody 4C2 and establishing a competitive ELISA detection method, the problems of low detection sensitivity and insufficient broad spectrum in existing technologies have been solved, realizing rapid and efficient serological detection, which is suitable for screening and diagnosing SARS-CoV-2 infection risk in humans and animals.
Patent Information
- Application Number
- CN202310496182.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-05
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2043-05-05
AI Technical Summary
Existing technologies for detecting novel coronavirus infection suffer from low sensitivity, high false negative rate, high cost, and long time. They are particularly difficult to meet urgent needs in large-scale sample testing, and serological testing methods lack the broad spectrum and specificity for SARS-CoV-2.
A monoclonal antibody 4C2 against SARS-CoV-2 N protein was prepared, and a competitive ELISA detection method based on this antibody was established. The method utilizes the antibody's high efficiency and specificity to recognize SARS-CoV-2 N protein, and achieves rapid and efficient serological detection through enzyme-labeled plate coating, incubation, and color development steps.
It enables rapid and efficient serological detection in humans and various animals, possesses high sensitivity and good stability, can effectively screen for SARS-CoV-2 infection risk, is suitable for broad-spectrum screening and serological epidemiological surveys, and has no cross-reaction with other pathogens.
Smart Images

Figure CN116514964B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to monoclonal antibodies that secrete SARS-CoV-2 N protein, their preparation methods and applications, and belongs to the field of biodetection technology. Background Technology
[0002] The novel coronavirus infection caused by SARS-CoV-2 poses a significant threat to economic development and human health. SARS-CoV-2 is the pathogen of COVID-19, mainly transmitted through close-range respiratory droplets and close contact. Its main symptoms include fever, dry cough, and fatigue. SARS-CoV-2 is a positive-sense RNA virus belonging to the β-coronavirus genus, with a genome length of approximately 30 kb. It shares about 80% homology with the SARS-CoV genome and 50% homology with MERS-CoV. SARS-CoV-2 is mainly composed of spike (S) protein, membrane (M) protein, envelope (E) protein, and nucleocapsid (N) protein. The N protein is the most abundant protein, which binds to RNA to form a helical nucleocapsid and is involved in genome replication and the regulation of cell signaling pathways.
[0003] As the novel coronavirus continues to mutate, various variants have emerged. Among the major SARS-CoV-2 variants, Alpha, Beta, and Gamma show missense mutations in the N protein, while other variants, including the latest Omicron variant, have mutations at different positions in the S protein. Furthermore, the N protein antibody binding site shows high consistency across different variants. In addition, antibodies against the N protein in serum tests have a longer duration of action than those against the S protein. This indicates that the N protein has significant potential as a broad-spectrum target for novel coronavirus antibody detection. Nucleic acid testing is the gold standard for early diagnosis of COVID-19. Commonly used nucleic acid testing methods include reverse transcription polymerase chain reaction (RT-PCR), high-throughput sequencing, and isothermal amplification. PCR methods are low-cost and fast, suitable for large samples in short timeframes, but have also revealed problems such as low sensitivity and high false-negative rates in practical testing. While whole-genome sequencing is accurate and comprehensive, it is time-consuming and costly, making it difficult to meet the urgent needs of large-scale sample testing. Serological testing can detect SARS-CoV-2 specific antibodies in blood sources such as serum, plasma, or whole blood, with the N protein being one of the most commonly used antigens. Summary of the Invention
[0004] This invention provides a monoclonal antibody against the SARS-CoV-2 N protein, its preparation method, and its application. It can enable rapid and efficient serological detection of humans and different animal species, and is of great significance for screening the risk of SARS-CoV-2 infection in humans and animals, as well as for serological epidemiological surveys.
[0005] The present invention also provides 4C2, a monoclonal antibody against SARS-CoV-2 N protein secreted by a hybridoma cell line or its passaged cell line.
[0006] The present invention also provides a polynucleotide containing a 4C2 monoclonal antibody encoding a polynucleotide.
[0007] This invention also provides the application of the competitive ELISA method based on the 4C2 monoclonal antibody in the detection of human and different animal serum.
[0008] The technical solution provided by this invention is as follows:
[0009] A monoclonal antibody against the SARS-CoV-2 N protein, the antibody comprising a heavy chain and a light chain; both the heavy chain and the light chain include a variable region, the variable region including a complementarity-determining region;
[0010] The complement determination regions CDR1, CDR2 and CDR3 of the heavy chain are represented by CDR-H1, CDR-H2 and CDR-H3, respectively.
[0011] The complementary determination regions CDR1, CDR2 and CDR3 of the light chain are represented by CDR-L1, CDR-L2 and CDR-L3, respectively.
[0012] The amino acid sequence of the CDR-H1 is shown in SEQ ID NO: 4;
[0013] The amino acid sequence of the CDR-H2 is shown in SEQ ID NO: 5;
[0014] The amino acid sequence of the CDR-H3 is shown in SEQ ID NO: 6;
[0015] The amino acid sequence of the CDR-L1 is shown in SEQ ID NO: 1;
[0016] The amino acid sequence of the CDR-L2 is shown in SEQ ID NO: 2;
[0017] The amino acid sequence of the CDR-L3 is shown in SEQ ID NO: 3.
[0018] Furthermore, the amino acid sequence of the light chain is shown in SEQ ID NO.7; the amino acid sequence of the heavy chain is shown in SEQ ID NO.9.
[0019] Another aspect of the present invention provides a nucleotide molecule that encodes the aforementioned antibody.
[0020] Furthermore, the nucleotide sequence encoding the light chain in the nucleotide molecule is shown in SEQ ID NO.8; the nucleotide sequence encoding the heavy chain in the nucleotide molecule is shown in SEQ ID NO.10.
[0021] Another aspect of the present invention provides a recombinant expression vector containing the above-mentioned nucleotide molecules.
[0022] Another aspect of the present invention provides a host cell containing or integrating the above-mentioned recombinant expression vector.
[0023] Another aspect of the present invention provides a method for preparing the above-mentioned SARS-CoV-2 N protein monoclonal antibody, comprising the following steps: preparing SARS-CoV-2 His-tagged N protein through a prokaryotic expression system; immunizing mice with SARS-CoV-2 His-tagged N protein and then fusing them with classical B-cell hybridoma technology, followed by subclonal cell culture; and obtaining SARS-CoV-2 N protein antibody.
[0024] Another aspect of the present invention provides the application of the above-mentioned antibodies, polynucleotides, recombinant expression vectors, and host cells in the preparation of SARS-CoV-2 detection reagents.
[0025] Another aspect of the present invention provides an ELISA detection composition comprising the antibody described above.
[0026] Furthermore, the composition also includes a solid-phase carrier coated with SARS-CoV-2 N protein, mouse positive serum and mouse negative serum immunized with SARS-CoV-2 N protein, coating solution, and blocking solution.
[0027] Furthermore, the combination also contains diluent, washing solution, TMB colorimetric solution, reaction termination solution, and other common experimental materials used by those skilled in the art in competitive ELISA detection.
[0028] Furthermore, the antibody is an enzyme-labeled antibody, specifically an HRP-labeled IgG antibody 4C2 targeting the SARS-CoV-2 N protein.
[0029] The solid-phase carrier is used to prepare an ELISA plate. The preparation method of the ELISA plate is as follows: using the checkerboard method, the prepared SARS-CoV-2 N protein is diluted with coating solution and added to each well of the ELISA plate for coating; then, after washing with washing solution, blocking solution is added to each well for blocking, and then washed with washing solution again.
[0030] Furthermore, the coating solution can be a carbonate buffer solution with pH 9.6; the washing solution is a PBST solution with pH 7.2; the blocking solution is 2% skim milk powder; the diluent is a PBS solution containing 1% BSA; and the reaction termination solution is a 0.5 mol / L H2SO4 solution.
[0031] Furthermore, the method specifically includes the following steps:
[0032] (1) Dilute the detection antigen with coating solution, wash with washing solution, block, and wash again;
[0033] (2) Add the negative and positive sera diluted with diluent and incubate;
[0034] (3) Add HRP-labeled 4C2 monoclonal antibody diluted with diluent, incubate, and wash;
[0035] (4) Add colorimetric solution, and after color development, add stop solution, detect OD450 value, and analyze the results.
[0036] Furthermore, the antigen coating concentration is 1 μg / mL; the coating time is 12 h; the blocking solution is 2% skim milk powder, and the blocking time is 3 h.
[0037] Furthermore, negative and positive sera diluted 1:10 with diluent were mixed 1:1 with HRP-labeled 4C2 monoclonal antibody diluted 1:12000 with diluent and added simultaneously to the blocked ELISA plate. The plate was then incubated at 37°C for 1 hour.
[0038] Furthermore, TMB colorimetric solution was added to each well and incubated at 37°C for 8 minutes.
[0039] Furthermore, the analysis results refer to the calculation of the inhibition rate PI = (1 - OD450 of serum sample / OD450 of blank control) × 100%. A serum sample PI ≥ 27.36% is judged as positive; a PI < 27.36% is judged as negative.
[0040] Beneficial effects
[0041] This invention selects SARS-CoV-2 N protein as an immunogen, prepares monoclonal antibodies that specifically recognize SARS-CoV-2 N protein, and establishes a competitive ELISA detection method for SARS-CoV-2. This method can realize rapid and efficient serological detection in humans and different animal species, and is of great significance for screening the risk of SARS-CoV-2 infection in humans and animals and for serological epidemiological surveys.
[0042] The monoclonal antibody 4C2 secreted by the hybridoma cell line provided in this invention has high titer and good specificity. The SARS-CoV-2 N protein competitive ELISA detection method established based on this antibody has high sensitivity, good stability, and no cross-reactivity with other pathogens. Therefore, this invention provides a sensitive and rapid detection method for animal infection with SARS-CoV-2, offering convenient technical support for the diagnosis of coronavirus infection in different animals in the livestock industry, and can thus be used for broad-spectrum screening of animals infected with different coronaviruses. Attached Figure Description
[0043] Figure 1 To identify the reactivity of monoclonal antibody 4C2 with antigen proteins;
[0044] Figure 2 This is a graph showing the indirect immunofluorescence results of monoclonal antibody 4C2.
[0045] Figure 3 Analysis of the reactivity of monoclonal antibody 4C2 with the N protein of the Omicron mutant strain;
[0046] Figure 4 For ROC curve analysis and sensitivity and specificity analysis;
[0047] Figure 5 To compete with ELISA specificity analysis results;
[0048] Figure 6 To analyze the results of the ELISA detection limit comparison. Detailed Implementation
[0049] To make the objectives, technical solutions, and beneficial effects of this invention clearer, the invention will be further described in detail below with reference to embodiments. Those skilled in the art can easily understand other advantages and effects of this invention from the content disclosed in this specification. Any modifications or substitutions made to the methods, steps, or conditions of this invention without departing from the spirit and substance of this invention are within the scope of this invention.
[0050] Example 1: Preparation of positive hybridomas and monoclonal antibodies
[0051] 1.1 Animal Immunity and Cell Fusion
[0052] Mice were initially immunized with SARS-CoV-2 His-N protein emulsified with Freund's complete adjuvant at 80 µg / mouse via multiple subcutaneous injections in the abdomen. A second immunization was administered 14 days later, with 80 µg / mouse of His-N protein emulsified with Freund's incomplete adjuvant via multiple subcutaneous injections in the abdomen. Seven days after the second immunization, serum antibody titers were measured. Fourteen days after the second immunization, mice were intraperitoneally immunized with His-N protein without adjuvant. Three days after the booster immunization, spleen cells were fused with logarithmic growth phase SP2 / 0 myeloma cells at a 1:5 ratio using 50% PEG. Peritoneal macrophages from ICR mice were used as feeder cells. The fused cells and feeder cells were suspended and mixed in HAT medium and seeded into 96-well plates, then cultured at 37°C. HAT medium was added after 5 days, and HT medium was used after 9 days.
[0053] 1.2 Indirect ELISA detection method for screening and cloning positive hybridoma cells
[0054] The ELISA plate was coated with the antigen at the optimal coating concentration determined by the matrix assay, using 1% BSA in PBS as the blocking solution. Hybridoma cell supernatant, SP2 / 0 cell supernatant, and immune mouse polyclonal antibody serum were used as the primary antibody, negative control, and positive control, respectively. Horseradish peroxidase (HRP)-labeled goat anti-mouse IgG at the working concentration was used as the secondary antibody. TMB was used for color development for 5 min. After color development, the OD450 value was measured using an ELISA reader. The experimental results were determined according to the following formula: OD450 cell well / OD450 negative well ≥ 2.1 was considered a positive well. The selected positive clone was named 4C2. The selected positive cell clone 4C2 was subcloned three times using the limiting dilution method and then preserved.
[0055] 1.3 Preparation and purification of 4C2 monoclonal antibody ascites
[0056] Healthy BALB / c mice aged 9-12 weeks were intraperitoneally injected with 0.5 mL of liquid paraffin per mouse. 7-10 days later, they were intraperitoneally inoculated with 4C2 hybridoma cells (2 × 10⁵ cells / mouse) diluted in PBS and cultured to the logarithmic growth phase. Ascites fluid was collected 7-10 days later, and the supernatant was collected by centrifugation and stored at -70°C. The prepared ascites fluid was purified using Protein A affinity chromatography, labeled with HRP, and stored at -70°C.
[0057] Example 2: Identification of 4C2 monoclonal antibody
[0058] 2.1 Identification of Monoclonal Antibody Subclasses
[0059] Monoclonal antibody subclass identification was performed using a monoclonal antibody subclass kit. Hybridoma cell culture supernatant was added to each well of a pre-coated ELISA plate (100 µL / well), and incubated at 37°C for 2 h. The plates were washed three times with PBST. Goat anti-mouse IgA, IgG1, IgG2a, IgG2b, IgG3, and IgM (1:1000 dilution in PBS) were added to each well (100 µL / well), and the plates were incubated at room temperature for 30 min. The plates were then washed three times with PBST. HRP-rabbit anti-goat IgG enzyme-labeled antibody (1:5000 dilution in PBS) was added to each well (100 µL / well), and the plates were incubated at room temperature for 15 min. The plates were washed five times with PBST. TMB chromogenic solution was added to each well (100 µL / well), and the plates were incubated at room temperature for 5 min. The reaction was terminated by adding 0.5 M H2SO4 (50 µL / well), and the OD450 was measured using a microplate reader. The monoclonal antibody subclass was determined based on the OD450 reading.
[0060] The results showed that the monoclonal antibody 4C2 subclass was IgG1.
[0061] The results showed that the amino acid sequence of the complementarity-determining region 1 (CDR1) of the variable region of the monoclonal antibody 4C2 light chain is as shown in SEQ ID NO.1, specifically: KSSQSLLYSSNQKNYLA.
[0062] The amino acid sequence of the complementary determinant region 2 (CDR2) of the light chain variable region is shown in SEQ ID NO.2, specifically: WASTRES.
[0063] The amino acid sequence of the complementarity-determining region 3 (CDR3) of the light chain variable region is shown in SEQ ID NO.3, specifically: QQYYRYPPT.
[0064] The amino acid sequence of the heavy chain variable region complementarity-determining region 1 (CDR1) is shown in SEQ ID NO.4, specifically: DSMH.
[0065] The amino acid sequence of the heavy chain variable region complementarity-determining region 2 (CDR2) is shown in SEQ ID NO.5, specifically: WINTETGEPAYADDFKG.
[0066] The amino acid sequence of the complementarity-determining region 3 (CDR3) of the heavy chain variable region is shown in SEQ ID NO.6, specifically: AVVADYYAMDY.
[0067] The full-length amino acid sequence of the light chain is shown in SEQ ID NO.7, specifically as follows:
[0068] MDSQAQVLMLLLLWVSGTCGDIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYRY PPTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC
[0069] The nucleotide sequence encoding the light chain is shown in SEQ ID NO.8, specifically:
[0070] ATGGATTCACAGGCCCAGGTTCTTATGTTACTGCTGCTATGGGTATCTGGTACCTGTGGGGACATTGTGATGTCACAGTCTCCATCCTCCCTAGCTGTGTCAGTTGGAGAGAAGTTACTATGAGCTGCAAGTCCAGTCAGAGCCTTTTATATAGTTCCAATCAAAAGAACTACTTGGCCTGGTACCAGCAGAAACCAGGGCAGTCTCCTAAACTGCTGATTTACTGGGCATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTGTGAAGGCTGAAGACCTGGCAGTTTATTACTGTCAGCAATATTATAGATATCCTCCCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAACGGGCTGATGCTGCACCAACTGTATCCATCTTCCCACCATCCAGTGAGCAGTTAACATCTGGAGGTGCCTCAGTCGTGTGCTTCTTGAACAACTTCTACCCCAAAGACATCAATGTCAAGTGGAAGATTGATGGCAGTGAACGACAAAATGGCGTCCTGAACAGTTGGACTGATCAGGACAGCAAAGACAGCACCTACAGCATGAGCAGCACCCTCACGTTGACCAAGGACGAGTATGAACGACATAACAGCTATACCTGTGAGGCCACTCACAAGACATCAACTTCACCCATTGTCAAGAGCTTCAACAGGAATGAGTGTTAG
[0071] The full-length amino acid sequence of the heavy chain is shown in SEQ ID NO. 9, specifically as follows:
[0072] MAWVWTLLFLMAAAQSNQAQIQLVQSGPELKKPGETVKISCKASGYTFTDSSMHWVKQAPGKGLKWMGWINTETGEPAYADDFKGRFAFSLETSASTAYLQINNLKNEDTSTYFCASAVVADYYAMDYWGQGSSVTVSSAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK
[0073] The nucleotide sequence encoding the heavy chain is shown in SEQ ID NO.10, specifically as follows:
[0074]
[0075] 2.2 Determination of monoclonal antibody ascites titer
[0076] Coat a 96-well ELISA plate with GST-N protein at the optimal coating concentration using coating buffer and incubate overnight at 4°C. Wash three times, add 200 µL of blocking buffer to each well, and incubate at 37°C for 2 h. Wash three times with PBST, add serially diluted monoclonal antibody ascites fluid, and use SP2 / 0 ascites fluid diluted at the same ratio as a negative control, and incubate at 37°C for 2 h. Wash five times with PBST. Add 100 µL / well of working concentration of HRP-goat anti-mouse IgG and incubate at 37°C for 1 h. After washing with PBST, add 100 µL / well of TMB chromogenic solution for color development and incubate at 37°C for 5 min. Stop the reaction by adding 0.5 M H2SO4. Detect the OD450 value using a microplate reader. Determine the monoclonal antibody ascites fluid titer with P / N ≥ 2.1 as the acceptance criterion.
[0077] The results showed that the titer of monoclonal antibody 4C2 was 1:20,480,000. The high titer of monoclonal antibody 4C2 indicates that the detection method established using it can produce high sensitivity.
[0078] 2.3 Identification of Monoclonal Antibody Immunoreactivity
[0079] His-tagged N protein and GST-tagged N protein were added to SDS buffer and incubated in a metal bath for 10 min for SDS-PAGE electrophoresis. The colloids were then transferred to an NC membrane using a rapid transfer instrument. PBST (5% skim milk powder) was used as blocking buffer. Working concentrations of monoclonal antibody 4C2 and HRP-goat anti-mouse enzyme-labeled antibody were used as primary and secondary antibodies, respectively. ECL staining was performed for 1 min, and images were captured using a high-sensitivity multi-functional imaging system.
[0080] The results are as follows Figure 1 As shown, the 4C2 monoclonal antibody exhibits good immunoreactivity.
[0081] 2.4 Monoclonal antibody specificity analysis
[0082] HEK-293T cells were cultured at a rate of 2 × 10⁵ cells / well in 24-well plates for approximately 16 h. Recombinant plasmids and empty vectors were transfected into the cells using Lipofectamine™ 2000, following the manufacturer's instructions. Indirect immunofluorescence assays were performed 24 h after transfection. Cells were fixed with ice-cold methanol and blocked with 5% BSA in PBST. Primary and secondary antibodies were prepared with 1:100 dilution of 4C2 monoclonal antibody cell supernatant and 1:1000 dilution of goat anti-mouse IgG-FITC. Mouse polyclonal antibody serum immunized with His-N protein was used as a positive control. The fluorescence intensity in the cells was observed under a fluorescence microscope, and photographs were taken and stored.
[0083] The results are as follows Figure 2 As shown, the 4C2 monoclonal antibody can specifically bind to the eukaryotically expressed SARS-CoV-2 N protein.
[0084] Example 3: Reactivity analysis of 4C2 monoclonal antibody with N protein of Omicron (BA.5.2) mutant strain
[0085] A pcDNA3.4 eukaryotic expression plasmid carrying the full-length gene sequence of the N protein of the SARS-CoV-2 Omicron (BA.5.2) mutant strain (Gene ID: WDQ79341.1) was constructed. After transfection into HEK-293T cells, the reactivity of the monoclonal antibody with the N protein of the Omicron mutant strain was analyzed by indirect immunofluorescence assay. The specific operation was the same as described in Example 2.4.
[0086] The results are as follows Figure 3 As shown, the 4C2 monoclonal antibody also exhibits strong specific recognition and binding ability with the N protein of the latest SARS-CoV-2 Omicron variant.
[0087] Example 4: Establishment of a Competitive ELISA Method
[0088] After optimizing the optimal coating concentration, blocking solution, blocking time, serum incubation time, serum dilution factor, enzyme-labeled antibody concentration, and substrate reaction time, the final procedure was established as follows: Coat with 1 μg / mL recombinant N protein overnight at 4℃, block with PBS containing 2% skim milk for 3 h, add 1:10 diluted serum and 1:12000 diluted enzyme-labeled antibody, incubate for 1 h; develop color with TMB for 8 min; terminate the reaction with 0.5 M H2SO4, and read the OD450 value using a microplate reader.
[0089] The competitive ELISA method established above was used to test 60 positive serum samples and 60 negative serum samples. The PI values were analyzed, and ROC curves were plotted using GraphPad Prism software.
[0090] The results are as follows Figure 4 The area under the curve was 1.000, P < 0.0001, indicating a highly significant difference. The inhibition rate of 27.36%, when the Youden's index was at its maximum, was selected as the threshold for this method, at which point both sensitivity and specificity were 100%. This means that a sample is considered positive when the inhibition rate is greater than 27.36%, and negative otherwise.
[0091] Example 5: Specificity detection using a competitive ELISA method
[0092] Following the competitive ELISA method established in Example 4, positive sera of 17 common pathogens, including Listeria monocytogenes, Salmonella Typhimurium, Campylobacter jejuni, Salmonella Enteritidis, Salmonella Pullorum, Salmonella Derby, Salmonella Infantis, Staphylococcus aureus, Escherichia coli, E. cloacae, Shigella sonnei, Newcastle disease virus (NDV), avian influenza virus (AIV), porcine epidemic diarrhea virus (PEDV), foot-and-mouth disease virus (FMDV), classical swine fever virus (CSFV), and porcine reproductive and respiratory syndrome virus (PRRSV), as well as positive sera from different animals (including mice, chickens, and pigs), were detected. Positive and negative controls were also established. Calculate the PI value for each serum sample to determine whether a nonspecific reaction exists.
[0093] The results are as follows Figure 5 This competitive ELISA method has good specificity and shows no cross-reactivity with positive sera from other common pathogens or positive sera from different animal infections.
[0094] Example 6: Determination of the detection limit of a competitive ELISA method
[0095] The purified 4C2 monoclonal antibody, with an original concentration of 2.7 mg / mL, was serially diluted at 1:10, 1:20, 1:40, 1:80, 1:160, 1:320, 1:640, 1:1280, 1:2560, 1:5120, and 1:10240 using the previously established indirect ELISA method. The PI value was then determined using the established competitive ELISA method, and the reaction curve was plotted.
[0096] The results are as follows Figure 6 The detection limit was calculated to be 106 ng / mL using the formula.
[0097] Example 7: Preliminary application of the SARS-CoV-2 N protein competition ELISA method
[0098] Forty-three human serum samples were tested using the competitive ELISA method established in this study, and the results were compared. Compared with chemiluminescent immunoassay, the sensitivity of the competitive ELISA method of this invention was 96.15%; the specificity was 94.12%; and the overall concordance rate was 95.13%. It also showed higher sensitivity than the commercially available SARS-CoV-2 Nucleocapsid Protein IgG Antibody ELISA Kit. Specific results are shown in Table 1, indicating that this method has good application prospects.
[0099] Table 1. Detection of serum samples
[0100]
[0101] The above embodiments are merely illustrative of the principles and effects of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by those skilled in the art without departing from the spirit and technical concept disclosed in the present invention should still be covered by the claims of the present invention.
Claims
1. A SARS-CoV-2 N protein monoclonal antibody, characterized in that, The antibody comprises a heavy chain and a light chain; both the heavy chain and the light chain include a variable region, and the variable region includes a complementarity-determining region. The complement determination regions CDR1, CDR2 and CDR3 of the heavy chain are represented by CDR-H1, CDR-H2 and CDR-H3, respectively. The complementary determination regions CDR1, CDR2 and CDR3 of the light chain are represented by CDR-L1, CDR-L2 and CDR-L3, respectively. The amino acid sequence of the CDR-H1 is shown in SEQ ID NO: 4; The amino acid sequence of the CDR-H2 is shown in SEQ ID NO: 5; The amino acid sequence of the CDR-H3 is shown in SEQ ID NO: 6; The amino acid sequence of the CDR-L1 is shown in SEQ ID NO: 1; The amino acid sequence of the CDR-L2 is shown in SEQ ID NO: 2; The amino acid sequence of the CDR-L3 is shown in SEQ ID NO:
3.
2. The SARS-CoV-2 N protein monoclonal antibody according to claim 1, characterized in that, The amino acid sequence of the light chain is shown in SEQ ID NO.7; the amino acid sequence of the heavy chain is shown in SEQ ID NO.
9.
3. A nucleotide molecule, characterized in that, The nucleotide molecule encodes a monoclonal antibody against the SARS-CoV-2 N protein as described in claim 1 or 2.
4. The nucleotide molecule according to claim 3, characterized in that, The sequences of the nucleotide molecule include SEQ ID NO: 8 and SEQ ID NO: 10; Sequence SEQ ID NO: 8 encodes the light chain variable region of the antibody described; The sequence SEQ ID NO: 10 encodes the heavy chain variable region of the antibody described.
5. An expression carrier, characterized in that, The expression vector contains the nucleotide molecules as described in claim 3 or 4.
6. A host cell, characterized in that, The host cell contains the expression vector as described in claim 5.
7. The use of the antibody of claim 1 or 2, the nucleotide molecule of claim 3 or 4, the expression vector of claim 5, or the host cell of claim 6 in the preparation of SARS-CoV-2 detection reagents.
8. A SARS-CoV-2 N detection kit, characterized in that, The kit contains the SARS-CoV-2 N protein monoclonal antibody as described in claim 1 or 2.
9. The SARS-CoV-2 N detection kit according to claim 8, characterized in that, The kit also includes a solid-phase carrier coated with SARS-CoV-2 N protein, mouse positive serum and mouse negative serum immunized with SARS-CoV-2 N protein.
Citation Information
Patent Citations
Single-chain antibody for resisting SARS-COV-2 virus N protein and application of single-chain antibody
CN111875700A
